A Study of Genetic Variation Influencing Pain and Response to Opioid Medications
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01293994|
Recruitment Status : Withdrawn (Do not have necessary resources to continue)
First Posted : February 11, 2011
Last Update Posted : November 22, 2016
|Condition or disease|
The investigators hope to find a genetic association with various physiologic responses to opioid medication in patients who suffer from chronic pain (e.g. OIH vs. analgesic tolerance, baseline pain sensitivity, etc.). This has never been done before, and if it proves successful, it could provide physicians a greater understanding of why some chronic opioid users continue needing increased doses of opioids. This data may also help predict which patients will do well with chronic opioid therapy and which ones may not. Initial data with OPRM1 gene analysis in humans already implicates certain SNPs with opioid responsiveness and there have been suggestions for screening patients for OPRM1 prior to initiating opioid therapy in order to optimize their treatment response (Reynolds et al., 2008).
Clin Lab Med. 2008 Dec;28(4):581-98. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy. Reynolds KK, Ramey-Hartung B, Jortani SA.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||A Study of Genetic Variation Influencing Pain and Response to Opioid Medications in Patients With Chronic Pain|
|Study Start Date :||February 2009|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
- Genetic association with various physiologic responses to opioid medication in patients [ Time Frame: Up to 5 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01293994
|United States, California|
|Stanford University School of Medicine|
|Stanford, California, United States, 94305|
|Principal Investigator:||Dr Larry Fu-nien Chu||Stanford University|